HCV Polymerase Inhibitor INX-189 Looks Promising in Early Study

Biopharmaceutical company Inhibitex this month announced preliminary clinical trial data indicating that its experimental nucleotide hepatitis C virus (HCV) polymerase inhibitor INX-189 appears safe and demonstrates good antiviral activity. In a small Phase 1b study of treatment-naive genotype 1 chronic hepatitis C patients treated for 7 days, the higher tested dose of INX-189, taken once-daily as monotherapy, lowered HCV viral load by about 1 log and reduced ALT levels.

Source and to read more: hivandhepatitis.com